NASDAQ:RETA

Reata Pharmaceuticals (RETA) Stock Forecast, Price & News

$172.36

0.00 (0.00%)

(As of 09/26/2023 ET)

Compare

Today's Range: $172.36
▼
$172.36
50-Day Range: $106.09
▼
$172.36
52-Week Range: $21.83
▼
$172.46

Volume: N/A
Average Volume: 778,243 shs
Market Capitalization: $6.58 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $150.36

Reata Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Hold
2.31 Rating Score
Upside/Downside: 12.8% Downside
$150.36 Price Target
Short Interest: Healthy
9.44% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.75
Upright™ Environmental Score
News Sentiment: 0.40
Based on 5 Articles This Week
Insider Trading: Selling Shares
$20.83 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.02) to ($2.71) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

567th out of 963 stocks

Pharmaceutical Preparations Industry

255th out of 451 stocks

2.2

Analyst's Opinion

Consensus Rating
Reata Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 4 buy ratings, 9 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $150.36, Reata Pharmaceuticals has a forecasted downside of 12.8% from its current price of $172.36.
Amount of Analyst Coverage
Reata Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.0

Short Interest

Percentage of Shares Shorted
9.44% of the float of Reata Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Reata Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Reata Pharmaceuticals has recently decreased by 8.08%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Reata Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Reata Pharmaceuticals does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Reata Pharmaceuticals has received a 78.64% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Reata Pharmaceuticals is -0.75.

1.9

News and Social Media Coverage

News Sentiment
Reata Pharmaceuticals has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Reata Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 3 people have searched for RETA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
Only 7 people have added Reata Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -30% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Reata Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,829,200.00 in company stock.
Percentage Held by Insiders
26.80% of the stock of Reata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Reata Pharmaceuticals are expected to grow in the coming year, from ($3.02) to ($2.71) per share.

See Top Rated MarketRank™ Stocks Here

About Reata Pharmaceuticals (NASDAQ:RETA) Stock

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

RETA Price History

30 days | 90 days | 365 days | Advanced Chart

RETA Stock News Headlines

September 26, 2023 | finanznachrichten.de

Biogen Inc.: Biogen Completes Acquisition of Reata Pharmaceuticals

September 26, 2023 | finance.yahoo.com

Biogen Completes Acquisition of Reata Pharmaceuticals

September 27, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.

September 24, 2023 | americanbankingnews.com

Reata Pharmaceuticals (NASDAQ:RETA) Coverage Initiated by Analysts at StockNews.com

September 19, 2023 | americanbankingnews.com

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) SVP Andrea Loewen Sells 3,175 Shares

September 18, 2023 | americanbankingnews.com

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Given Average Rating of "Hold" by Brokerages

September 13, 2023 | finance.yahoo.com

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Is Expected To Breakeven In The Near Future

September 9, 2023 | finance.yahoo.com

Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?

September 27, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

August 28, 2023 | businesswire.com

REATA PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale ...

August 15, 2023 | msn.com

Cantor Fitzgerald Reiterates Reata Pharmaceuticals Inc - (RETA) Neutral Recommendation

August 11, 2023 | benzinga.com

Reata Pharmaceuticals Unusual Options Activity For August 11

August 9, 2023 | markets.businessinsider.com

Reata Pharmaceuticals (RETA) Gets a Hold from Barclays

August 2, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RETA, EQRX, RVMD

August 2, 2023 | msn.com

Reata Pharmaceuticals Inc - (RETA) Price Target Increased by 53.21% to 175.90

July 29, 2023 | msn.com

Biogen's Bold $7.3B Acquisition Of Reata: Analyzing The Impact On Investors

July 28, 2023 | investing.com

Biogen agrees to acquire neurological disease specialist Reata Pharmaceuticals at 60% premium

July 28, 2023 | technews.tmcnet.com

RETA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Reata Pharmaceuticals, Inc. Is Fair to Shareholders

July 28, 2023 | finance.yahoo.com

Biogen to Acquire Reata Pharmaceuticals

July 28, 2023 | marketwatch.com

Reata Pharmaceuticals Shares Soar on Takeover by Biogen >RETA

July 28, 2023 | markets.businessinsider.com

Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?

July 24, 2023 | markets.businessinsider.com

Expert Ratings for Reata Pharmaceuticals

July 6, 2023 | msn.com

TD Cowen starts Reata at outperform, cites sales potential of ataxia drug

June 30, 2023 | nasdaq.com

Ladenburg Thalmann Maintains Reata Pharmaceuticals Inc - (RETA) Buy Recommendation

June 29, 2023 | msn.com

Cantor Fitzgerald Reiterates Reata Pharmaceuticals Inc - (RETA) Overweight Recommendation

June 28, 2023 | markets.businessinsider.com

SVB Securities Reaffirms Their Buy Rating on Reata Pharmaceuticals (RETA)

June 28, 2023 | markets.businessinsider.com

Goldman Sachs Sticks to Its Buy Rating for Reata Pharmaceuticals (RETA)

See More Headlines

Receive RETA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RETA Company Calendar

Last Earnings: 8/08/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RETA
CUSIP: N/A
CIK: 1358762
Web: www.reatapharma.com
Phone: (972) 865-2219
Fax: N/A
Employees: 321
Year Founded: 2002

Price Target and Rating

Average Stock Price Forecast: $150.36
High Stock Price Forecast: $173.00
Low Stock Price Forecast: $75.00
Forecasted Upside/Downside: -12.8%
Consensus Rating: Hold
Rating Score (0-4): 2.31
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-311,900,000.00
Net Margins: N/A
Pretax Margin: -373.40%
Return on Equity: -922.50%
Return on Assets: -73.39%

Debt

Debt-to-Equity Ratio: 0.84
Current Ratio: 3.21
Quick Ratio: 3.19

Sales & Book Value

Annual Sales: $2.22 million
Price / Sales: 2,961.95
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.79) per share
Price / Book: -96.29

Miscellaneous

Outstanding Shares: 38,150,000
Free Float: 27,926,000
Market Cap: $6.58 billion
Optionable: Optionable
Beta: 1.42

Social Links

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. J. Warren Huff (Age 69)
Chairman, CEO & Sec.
Comp: $1.11M

Mr. Manmeet Singh Soni (Age 45)
COO, CFO & Pres
Comp: $1.02M

Mr. Michael D. Wortley (Age 75)
Exec. VP and Chief Legal & Compliance Officer
Comp: $773.06k

Dr. Colin J. Meyer M.D. (Age 44)
Exec. VP & Chief Innovation Officer
Comp: $842.4k

Ms. Dawn Carter Bir (Age 52)
Exec. VP & Chief Commercial Officer
Comp: $652.39k

Mr. Bhaskar Anand (Age 45)
Sr. VP & Chief Accounting Officer

Dr. W. Christian Wigley Ph.D.
Sr. VP & Chief Scientific Officer

Mr. Steve Harman
Sr. VP & Chief HR Officer

Dr. Samina Khan M.D. (Age 58)
Chief Medical Officer & Sr. VP

Mr. Dakota Gallivan
VP & Chief Healthcare Compliance Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RETA Stock - Frequently Asked Questions

Should I buy or sell Reata Pharmaceuticals stock right now?: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RETA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RETA, but not buy additional shares or sell existing shares.
View RETA analyst ratings or view top-rated stocks.
What is Reata Pharmaceuticals' stock price forecast for 2023?: 13 Wall Street analysts have issued 12-month target prices for Reata Pharmaceuticals' stock. Their RETA share price forecasts range from $75.00 to $173.00. On average, they predict the company's share price to reach $150.36 in the next year. This suggests that the stock has a possible downside of 12.8%.
View analysts price targets for RETA or view top-rated stocks among Wall Street analysts.
How have RETA shares performed in 2023?: Reata Pharmaceuticals' stock was trading at $37.99 at the beginning of 2023. Since then, RETA stock has increased by 353.7% and is now trading at $172.36.
View the best growth stocks for 2023 here.
When is Reata Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our RETA earnings forecast.
How were Reata Pharmaceuticals' earnings last quarter?: Reata Pharmaceuticals, Inc. (NASDAQ:RETA) issued its quarterly earnings data on Tuesday, August, 8th. The company reported ($2.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.88) by $0.56. The business had revenue of $22.75 million for the quarter, compared to analyst estimates of $0.85 million.
What ETFs hold Reata Pharmaceuticals' stock?: ETFs with the largest weight of Reata Pharmaceuticals (NASDAQ:RETA) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Virtus LifeSci Biotech Products ETF (BBP), Subversive Mental Health ETF (SANE), iShares U.S. Pharmaceuticals ETF (IHE), BlackRock Future Health ETF (BMED), Principal Healthcare Innovators ETF (BTEC) and Invesco DWA SmallCap Momentum ETF (DWAS).
What is Warren Huff's approval rating as Reata Pharmaceuticals' CEO?: 10 employees have rated Reata Pharmaceuticals Chief Executive Officer Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among the company's employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Reata Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).

When did Reata Pharmaceuticals IPO?: (RETA) raised $60 million in an initial public offering on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.
What is Reata Pharmaceuticals' stock symbol?: Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."
Who are Reata Pharmaceuticals' major shareholders?: Reata Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.76%), Boxer Capital LLC (3.81%), State Street Corp (1.90%), Perceptive Advisors LLC (1.76%), Holocene Advisors LP (1.78%) and Geode Capital Management LLC (1.58%). Insiders that own company stock include Andrea Loewen, Bhaskar Anand, Colin John Meyer, Dawn Carter Bir, Elaine Castellanos, James Warren Huff, Manmeet Singh Soni, Michael D Wortley, Samina Khan and Shamim Ruff.
View institutional ownership trends.
How do I buy shares of Reata Pharmaceuticals?: Shares of RETA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Reata Pharmaceuticals' stock price today?: One share of RETA stock can currently be purchased for approximately $172.36.
How much money does Reata Pharmaceuticals make?: Reata Pharmaceuticals (NASDAQ:RETA) has a market capitalization of $6.58 billion and generates $2.22 million in revenue each year.
How many employees does Reata Pharmaceuticals have?: The company employs 321 workers across the globe.
How can I contact Reata Pharmaceuticals?: Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The official website for the company is www.reatapharma.com. The company can be reached via phone at (972) 865-2219 or via email at ir@reatapharma.com.

This page (NASDAQ:RETA) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial